DSpace About DSpace Software
 

DSpace Biblioteca Universidad de Talca (v1.5.2) >
Dirección de Investigación >
Artículos en publicaciones ISI - Universidad de Talca >

Please use this identifier to cite or link to this item: http://dspace.utalca.cl/handle/1950/4876

Title: The AP-1/NF-kappa B double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia
Authors: Moore-Carrasco, R.
Busquets, S.
Almendro, V.
Palanki, M.
Lopez-Soriano, F.J.
Argiles, J.M.
Keywords: SP100030; AP-1; nuclear factor-kappa B; skeletal muscle; cachexia
Issue Date: 2007
Publisher: Spandidos Publications Ltd.
Citation: International Journal of Oncology 30(5):1239 -1245
Abstract: Daily treatment of rats bearing the cachectic Yoshida AH-130 ascites hepatoma with the double inhibitor of NF-κB and AP-1 SP100030 at a dose of 1 mg/kg of body weight resulted in a clear amelioration of the cachectic effect, especially at the level of skeletal muscle. Thus, tumour-bearing rats treated with SP100030 showed a significant recovery in the weights of gastrocnemius, EDL, tibialis and cardiac muscles. In addition, treatment with the inhibitor affected both liver and kidney weights. The amelioration in muscle weight was accompanied by an increase in MyoD gene expression, the main transcription factor of muscle tissue involved in muscle differentiation, in gastrocnemius muscle. At the dose used in this study, SP100030 was an effective inhibitor of AP-1; however, the NF-κB transcription factor was not affected. The effects of the inhibitor seem to be at the level of proteolysis since lower total proteolytic rates were found when incubating isolated rat muscles in the presence of SP100030. The inhibitor influenced the gene expression of the ubiquitin-conjugating enzyme E214K in skeletal muscle of tumour-bearing rats; this enzyme seems to be the main regulator of the activity of the main proteolytic system involved during cancer cachexia, the ubiquitin-proteasome system. In conclusion, treatment of cachectic tumour-bearing rats with SP100030 results in an amelioration of the muscle wasting effect, suggesting that the AP-1 signaling cascade plays an important role in the signaling of muscle wasting associated with disease.
Description: Moore-Carrasco, R. Department of Clinical Biochemistry and Immunohematology, Faculty of Health Sciences, Universidad de Talca, Casilla N° 747, Talca.
URI: http://dspace.utalca.cl/handle/1950/4876
ISSN: 1019-6439
Appears in Collections:Artículos en publicaciones ISI - Universidad de Talca

Files in This Item:

There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2009  The DSpace Foundation - Feedback